{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T11:19:40Z","timestamp":1742383180794,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,11,12]],"date-time":"2016-11-12T00:00:00Z","timestamp":1478908800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R21CA180997"],"award-info":[{"award-number":["R21CA180997"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s00520-016-3467-9","type":"journal-article","created":{"date-parts":[[2016,11,12]],"date-time":"2016-11-12T22:26:47Z","timestamp":1478989607000},"page":"833-838","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A proof-of-concept trial of protein kinase C iota inhibition with auranofin for the paclitaxel-induced acute pain syndrome"],"prefix":"10.1007","volume":"25","author":[{"given":"Aminah","family":"Jatoi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan E.","family":"Grudem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Travis J.","family":"Dockter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew S.","family":"Block","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose C.","family":"Villasboas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelina","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Deering","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pashtoon M.","family":"Kasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron S.","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana Perez","family":"Botero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott H.","family":"Okuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deanne R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan P.","family":"Fields","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,12]]},"reference":[{"key":"3467_CR1","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMoa1505067","volume":"374","author":"JK Chan","year":"2016","unstructured":"Chan JK, Brady MF, Penson RT et al (2016) Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med 374:738\u2013748","journal-title":"N Engl J Med"},{"key":"3467_CR2","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P Van Hagen","year":"2012","unstructured":"Van Hagen P, Hulshof MC, van Lanschot JJ et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074\u20132084","journal-title":"N Engl J Med"},{"key":"3467_CR3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1406281","volume":"372","author":"SM Tolaney","year":"2015","unstructured":"Tolaney SM, Barry WT, Dang CT et al (2015) Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 372:134\u2013141","journal-title":"N Engl J Med"},{"key":"3467_CR4","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1200\/JCO.2015.62.6812","volume":"33","author":"WE Eberhardt","year":"2015","unstructured":"Eberhardt WE, Pottgen C, Gauler TC et al (2015) Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIA(N2) and selected IIIB non-small cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy. J Clin Oncol 33:4194\u20134201","journal-title":"J Clin Oncol"},{"key":"3467_CR5","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1200\/JCO.2014.58.4391","volume":"33","author":"R Kitagawa","year":"2015","unstructured":"Kitagawa R, Katsumata N, Shibata T et al (2015) Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol 33:2129\u20132135","journal-title":"J Clin Oncol"},{"key":"3467_CR6","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1200\/JCO.2010.33.0308","volume":"29","author":"CL Loprinzi","year":"2011","unstructured":"Loprinzi CL, Reeves BN, Dakhil SR et al (2011) Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol 29:1472\u20131478","journal-title":"J Clin Oncol"},{"key":"3467_CR7","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3747\/co.v17i4.562","volume":"17","author":"S Saibil","year":"2010","unstructured":"Saibil S, Fitgerald B, Freedman OC et al (2010) Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey. Curr Oncl 17:42","journal-title":"Curr Oncl"},{"key":"3467_CR8","doi-asserted-by":"crossref","unstructured":"Chiu N, Chiu L, Chow R, et al. 2016 Taxane-induced arthralgia and myalgia: a literature review. J Oncology Pharmacy Practice","DOI":"10.1177\/1078155215627502"},{"key":"3467_CR9","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1200\/JCO.1993.11.10.2010","volume":"11","author":"EK Rowinsky","year":"1993","unstructured":"Rowinsky EK, Chaudry V, Forestiere AA et al (1993) Phase 1 pharmacologic study of paclitaxel and cisplatin with granulocyte colony stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol 11:2010\u20132020","journal-title":"J Clin Oncol"},{"key":"3467_CR10","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1158\/1541-7786.MCR-13-0371-T","volume":"11","author":"Y Wang","year":"2013","unstructured":"Wang Y, Hill KS, Fields AP (2013) Protein kinase C iota maintains a tumor-initiating phenotype that is required for ovarian tumorigenesis. Mol Cancer Res 11:1624\u20131635","journal-title":"Mol Cancer Res"},{"key":"3467_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2013.10.023","volume":"88","author":"PJ Parker","year":"2014","unstructured":"Parker PJ, Justilien V, Riou P, Linch M, Fields AP (2014) Atypical protein kinase C iota as a human oncologene and therapeutic target. Biochem Pharmacol 88:1\u201311","journal-title":"Biochem Pharmacol"},{"key":"3467_CR12","doi-asserted-by":"crossref","first-page":"15297","DOI":"10.18632\/oncotarget.3812","volume":"6","author":"AM Butler","year":"2015","unstructured":"Butler AM, Cotti Buzhardt ML, Erdogan E, Li S, Inman KS, Fields AP, Murray NR (2015) A small molecule inhibitor of atypical protein kinase C signaling inhibits pancreatic cancer cell transformed growth and invasion. Oncotarget 6:15297\u201315310","journal-title":"Oncotarget"},{"key":"3467_CR13","first-page":"2469","volume":"274","author":"L Jamieson","year":"1999","unstructured":"Jamieson L, Carpenter L, Biden TJ et al (1999) Protein kinase C iota activity is necessary for BCR-Abl-mediated resistance to drug-induced apoptosis. J Biol Chem 274:2469\u20132476","journal-title":"J Biol Chem"},{"key":"3467_CR14","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/onc.2012.46","volume":"32","author":"K Kikuchi","year":"2013","unstructured":"Kikuchi K, Soundararajan A, Zarzabal LA et al (2013) Protein kinase C iota as a therapeutic target in alveolar rhabdomyosarcoma. Oncogene 32:286\u2013295","journal-title":"Oncogene"},{"key":"3467_CR15","doi-asserted-by":"crossref","first-page":"24124","DOI":"10.1074\/jbc.M601905200","volume":"281","author":"ER LaVallie","year":"2006","unstructured":"LaVallie ER, Chockalingam PS, Collins-Racie LA et al (2006) Protein kinase C zeta is upregulated in osteoarthritis cartilage and is required for activation of NF-kappaB by tumor necrosis factor and interleukin-1 in particular chondrocytes. J Biol Chem 281:24124\u201324137","journal-title":"J Biol Chem"},{"issue":"Suppl 1","key":"3467_CR16","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/03008200390152214","volume":"44","author":"BD Boyan","year":"2003","unstructured":"Boyan BD, Dean DD, Sylvia VL, Schwartz Z (2003) Steroid hormone action in musculoskeletal cells involves membrane receptor mechanisms. Connect Tissue Res 44(Suppl 1):130\u2013135","journal-title":"Connect Tissue Res"},{"key":"3467_CR17","first-page":"371","volume":"6","author":"KT Valazquez","year":"2007","unstructured":"Valazquez KT, Mohammad H, Sweitzer SM (2007) Protein kinase C in pain: involvement of multiple isoforms. Pharmacol Res 6:371\u2013384","journal-title":"Pharmacol Res"},{"key":"3467_CR18","doi-asserted-by":"crossref","first-page":"E385","DOI":"10.1152\/ajpendo.00608.2009","volume":"298","author":"RV Farese","year":"2010","unstructured":"Farese RV, Sajan MP (2010) Metabolic functions of atypical protein kinase C: \u201cgood\u201d and \u201cbad\u201d as defined by nutritional status. Am J Physiol Endocrin Metab 298:E385\u2013E394","journal-title":"Am J Physiol Endocrin Metab"},{"key":"3467_CR19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.tem.2007.11.005","volume":"19","author":"F Bequinot","year":"2008","unstructured":"Bequinot F, Fromisano P (2008) Atypical protein kinase C and the metabolic syndrome. Trends Endocrinol Metab 19:39\u201341","journal-title":"Trends Endocrinol Metab"},{"key":"3467_CR20","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1517\/13543784.10.9.1653","volume":"10","author":"J Kamei","year":"2001","unstructured":"Kamei J, Mizoguchi H, Narita M et al (2001) Therapeutic potential of PKC inhibitors in pain diabetic neuropathy. Expert Opinon Investig Drugs 10:1653\u20131664","journal-title":"Expert Opinon Investig Drugs"},{"key":"3467_CR21","unstructured":"Chaffman M, Brogden RN, Heel RC et al (1987) Auranofin: a preliminary review of its pharmacological properties and therapeutics use in rheumatoid arthritis. Adis 27"},{"key":"3467_CR22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2307\/2529712","volume":"31","author":"SJ Pocock","year":"1975","unstructured":"Pocock SJ, Simon R (1975) Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103\u2013115","journal-title":"Biometrics"},{"key":"3467_CR23","first-page":"496","volume":"10","author":"EH Giannini","year":"1983","unstructured":"Giannini EH, Person DA, Brewer EJ, Parks DB (1983) Blood and serum concentrations of gold after a single dose of auranofin in children with juvenile rheumatoid arthritis. J Rheumatol 10:496\u2013498","journal-title":"J Rheumatol"},{"key":"3467_CR24","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","volume":"34","author":"E Basch","year":"2016","unstructured":"Basch E, Deal AM, Kris MG et al (2016) Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 34:557\u2013565","journal-title":"J Clin Oncol"},{"key":"3467_CR25","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.2013.53.5948","volume":"32","author":"G Kotronoulas","year":"2014","unstructured":"Kotronoulas G, Kearney N, Maguire R et al (2014) What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. J Clin Oncol 32:1480\u20131501","journal-title":"J Clin Oncol"},{"key":"3467_CR26","doi-asserted-by":"crossref","unstructured":"Chiu N, Zhang L, Gallo-Herschberg D, et al. 2016 Which pain intensity scale from the Brief Pain Inventory correlates most highly with functional interference scores in patients experiencing taxane-induced arthralgia and myalgia? Support Care Cancer","DOI":"10.1007\/s00520-016-3106-5"},{"key":"3467_CR27","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.clon.2007.04.007","volume":"19","author":"K Harris","year":"2007","unstructured":"Harris K, Li K, Flynn C, Chow E (2007) Worse, average, or current pain in the brief pain inventory: which should be used to calculate the response to palliative radiotherapy in patients with bone metastases? Clin Oncol 19:523\u2013527","journal-title":"Clin Oncol"},{"key":"3467_CR28","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00002508-200409000-00005","volume":"20","author":"S Keller","year":"2004","unstructured":"Keller S, Bann CM, Dodd SL et al (2004) Validity of the Brief Pain Inventory for use in documenting the outcomes of patients with non-cancer pain. Clin J Pain 20:309\u2013318","journal-title":"Clin J Pain"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-016-3467-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-016-3467-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-016-3467-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T06:09:11Z","timestamp":1657692551000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-016-3467-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,12]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["3467"],"URL":"https:\/\/doi.org\/10.1007\/s00520-016-3467-9","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2016,11,12]]}}}